The global Bevacizumab market is projected to grow from US$ 63 million in 2024 to US$ 82 million by 2030, at a Compound Annual Growth Rate (CAGR) of 4.4% during the forecast period.

Bevacizumab Market

Bevacizumab, sold under the trade name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease.

Bevacizumab is a monoclonal antibody used for the treatment of various types of cancer, including colorectal, lung, breast, and kidney cancers. The global market for bevacizumab is being driven by several factors. The global prevalence of cancer is on the rise, primarily due to factors such as aging population, lifestyle changes, and environmental factors. This has led to a higher demand for effective cancer therapies like bevacizumab. Bevacizumab is considered a targeted therapy as it selectively inhibits the growth of blood vessels that feed tumors, thereby suppressing tumor growth and progression. The growing preference for targeted therapies among healthcare providers and patients is driving the market for bevacizumab. Bevacizumab has received regulatory approvals for the treatment of various types of cancers, including advanced colorectal, non-small cell lung, metastatic breast, and renal cell carcinoma. The expanding list of approved indications is contributing to the market growth. Improvements in healthcare infrastructure, particularly in emerging markets, have increased access to advanced cancer therapies like bevacizumab. This has led to a wider patient pool and increased market demand. Governments and private entities are investing heavily in healthcare, including cancer treatment. This increased healthcare spending is supporting the availability and affordability of bevacizumab, driving market growth.

Report Covers:

This report presents an overview of global market for Bevacizumab, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Bevacizumab, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Bevacizumab, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Bevacizumab sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Bevacizumab market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Bevacizumab sales, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Bevacizumab Market Report

Report Metric	Details
Report Name	Bevacizumab Market
Accounted market size in 2024	US$ 63 million
Forecasted market size in 2030	US$ 82 million
CAGR	4.4
Base Year	2024
Forecasted years	2025 - 2030
Segment by Type	Avastin (bevacizumab) Mvasi (bevacizumab-awwb)
Segment by Application	Cancer Eye Diease
Segment by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Aark Pharmaceuticals, Beacon Pharmaceuticals Limited, Balaji Medical Services Private Limited, MVASI (bevacizumab), Mylan
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Bevacizumab in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Bevacizumab manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bevacizumab sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

FAQ for this report

How fast is Bevacizumab Market growing?

Ans: The Bevacizumab Market witnessing a CAGR of 4.4 during the forecast period 2025-2030.

What is the Bevacizumab Market size in 2030?

Ans: The Bevacizumab Market size in 2030 will be US$ 82 million.

Who are the main players in the Bevacizumab Market report?

Ans: The main players in the Bevacizumab Market are Aark Pharmaceuticals, Beacon Pharmaceuticals Limited, Balaji Medical Services Private Limited, MVASI (bevacizumab), Mylan

What are the Application segmentation covered in the Bevacizumab Market report?

Ans: The Applications covered in the Bevacizumab Market report are Cancer, Eye Diease

What are the Type segmentation covered in the Bevacizumab Market report?

Ans: The Types covered in the Bevacizumab Market report are Avastin (bevacizumab), Mvasi (bevacizumab-awwb)

1 Study Coverage

1.1 Bevacizumab Product Introduction

1.2 Market by Type

1.2.1 Global Bevacizumab Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Avastin (bevacizumab)

1.2.3 Mvasi (bevacizumab-awwb)

1.3 Market by Application

1.3.1 Global Bevacizumab Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Cancer

1.3.3 Eye Diease

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Bevacizumab Sales Estimates and Forecasts 2019-2030

2.2 Global Bevacizumab Revenue by Region

2.2.1 Global Bevacizumab Revenue by Region: 2019 VS 2023 VS 2030

2.2.2 Global Bevacizumab Revenue by Region (2019-2024)

2.2.3 Global Bevacizumab Revenue by Region (2025-2030)

2.2.4 Global Bevacizumab Revenue Market Share by Region (2019-2030)

2.3 Global Bevacizumab Sales Estimates and Forecasts 2019-2030

2.4 Global Bevacizumab Sales by Region

2.4.1 Global Bevacizumab Sales by Region: 2019 VS 2023 VS 2030

2.4.2 Global Bevacizumab Sales by Region (2019-2024)

2.4.3 Global Bevacizumab Sales by Region (2025-2030)

2.4.4 Global Bevacizumab Sales Market Share by Region (2019-2030)

2.5 US & Canada

2.6 Europe

2.7 China

2.8 Asia (excluding China)

2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

3.1 Global Bevacizumab Sales by Manufacturers

3.1.1 Global Bevacizumab Sales by Manufacturers (2019-2024)

3.1.2 Global Bevacizumab Sales Market Share by Manufacturers (2019-2024)

3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Bevacizumab in 2023

3.2 Global Bevacizumab Revenue by Manufacturers

3.2.1 Global Bevacizumab Revenue by Manufacturers (2019-2024)

3.2.2 Global Bevacizumab Revenue Market Share by Manufacturers (2019-2024)

3.2.3 Global Top 10 and Top 5 Companies by Bevacizumab Revenue in 2023

3.3 Global Key Players of Bevacizumab, Industry Ranking, 2022 VS 2023 VS 2024

3.4 Global Bevacizumab Sales Price by Manufacturers

3.5 Analysis of Competitive Landscape

3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

3.5.2 Global Bevacizumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.6 Global Key Manufacturers of Bevacizumab, Manufacturing Base Distribution and Headquarters

3.7 Global Key Manufacturers of Bevacizumab, Product Offered and Application

3.8 Global Key Manufacturers of Bevacizumab, Date of Enter into This Industry

3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

4.1 Global Bevacizumab Sales by Type

4.1.1 Global Bevacizumab Historical Sales by Type (2019-2024)

4.1.2 Global Bevacizumab Forecasted Sales by Type (2025-2030)

4.1.3 Global Bevacizumab Sales Market Share by Type (2019-2030)

4.2 Global Bevacizumab Revenue by Type

4.2.1 Global Bevacizumab Historical Revenue by Type (2019-2024)

4.2.2 Global Bevacizumab Forecasted Revenue by Type (2025-2030)

4.2.3 Global Bevacizumab Revenue Market Share by Type (2019-2030)

4.3 Global Bevacizumab Price by Type

4.3.1 Global Bevacizumab Price by Type (2019-2024)

4.3.2 Global Bevacizumab Price Forecast by Type (2025-2030)

5 Market Size by Application

5.1 Global Bevacizumab Sales by Application

5.1.1 Global Bevacizumab Historical Sales by Application (2019-2024)

5.1.2 Global Bevacizumab Forecasted Sales by Application (2025-2030)

5.1.3 Global Bevacizumab Sales Market Share by Application (2019-2030)

5.2 Global Bevacizumab Revenue by Application

5.2.1 Global Bevacizumab Historical Revenue by Application (2019-2024)

5.2.2 Global Bevacizumab Forecasted Revenue by Application (2025-2030)

5.2.3 Global Bevacizumab Revenue Market Share by Application (2019-2030)

5.3 Global Bevacizumab Price by Application

5.3.1 Global Bevacizumab Price by Application (2019-2024)

5.3.2 Global Bevacizumab Price Forecast by Application (2025-2030)

6 US & Canada

6.1 US & Canada Bevacizumab Market Size by Type

6.1.1 US & Canada Bevacizumab Sales by Type (2019-2030)

6.1.2 US & Canada Bevacizumab Revenue by Type (2019-2030)

6.2 US & Canada Bevacizumab Market Size by Application

6.2.1 US & Canada Bevacizumab Sales by Application (2019-2030)

6.2.2 US & Canada Bevacizumab Revenue by Application (2019-2030)

6.3 US & Canada Bevacizumab Market Size by Country

6.3.1 US & Canada Bevacizumab Revenue by Country: 2019 VS 2023 VS 2030

6.3.2 US & Canada Bevacizumab Sales by Country (2019-2030)

6.3.3 US & Canada Bevacizumab Revenue by Country (2019-2030)

6.3.4 US

6.3.5 Canada

7 Europe

7.1 Europe Bevacizumab Market Size by Type

7.1.1 Europe Bevacizumab Sales by Type (2019-2030)

7.1.2 Europe Bevacizumab Revenue by Type (2019-2030)

7.2 Europe Bevacizumab Market Size by Application

7.2.1 Europe Bevacizumab Sales by Application (2019-2030)

7.2.2 Europe Bevacizumab Revenue by Application (2019-2030)

7.3 Europe Bevacizumab Market Size by Country

7.3.1 Europe Bevacizumab Revenue by Country: 2019 VS 2023 VS 2030

7.3.2 Europe Bevacizumab Sales by Country (2019-2030)

7.3.3 Europe Bevacizumab Revenue by Country (2019-2030)

7.3.4 Germany

7.3.5 France

7.3.6 U.K.

7.3.7 Italy

7.3.8 Russia

8 China

8.1 China Bevacizumab Market Size

8.1.1 China Bevacizumab Sales (2019-2030)

8.1.2 China Bevacizumab Revenue (2019-2030)

8.2 China Bevacizumab Market Size by Application

8.2.1 China Bevacizumab Sales by Application (2019-2030)

8.2.2 China Bevacizumab Revenue by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Bevacizumab Market Size by Type

9.1.1 Asia Bevacizumab Sales by Type (2019-2030)

9.1.2 Asia Bevacizumab Revenue by Type (2019-2030)

9.2 Asia Bevacizumab Market Size by Application

9.2.1 Asia Bevacizumab Sales by Application (2019-2030)

9.2.2 Asia Bevacizumab Revenue by Application (2019-2030)

9.3 Asia Bevacizumab Sales by Region

9.3.1 Asia Bevacizumab Revenue by Region: 2019 VS 2023 VS 2030

9.3.2 Asia Bevacizumab Revenue by Region (2019-2030)

9.3.3 Asia Bevacizumab Sales by Region (2019-2030)

9.3.4 Japan

9.3.5 South Korea

9.3.6 China Taiwan

9.3.7 Southeast Asia

9.3.8 India

10 Middle East, Africa and Latin America

10.1 Middle East, Africa and Latin America Bevacizumab Market Size by Type

10.1.1 Middle East, Africa and Latin America Bevacizumab Sales by Type (2019-2030)

10.1.2 Middle East, Africa and Latin America Bevacizumab Revenue by Type (2019-2030)

10.2 Middle East, Africa and Latin America Bevacizumab Market Size by Application

10.2.1 Middle East, Africa and Latin America Bevacizumab Sales by Application (2019-2030)

10.2.2 Middle East, Africa and Latin America Bevacizumab Revenue by Application (2019-2030)

10.3 Middle East, Africa and Latin America Bevacizumab Sales by Country

10.3.1 Middle East, Africa and Latin America Bevacizumab Revenue by Country: 2019 VS 2023 VS 2030

10.3.2 Middle East, Africa and Latin America Bevacizumab Revenue by Country (2019-2030)

10.3.3 Middle East, Africa and Latin America Bevacizumab Sales by Country (2019-2030)

10.3.4 Brazil

10.3.5 Mexico

10.3.6 Turkey

10.3.7 Israel

10.3.8 GCC Countries

11 Company Profiles

11.1 Genentech

11.1.1 Genentech Company Information

11.1.2 Genentech Overview

11.1.3 Genentech Bevacizumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.1.4 Genentech Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

11.1.5 Genentech Recent Developments

11.2 Amgen

11.2.1 Amgen Company Information

11.2.2 Amgen Overview

11.2.3 Amgen Bevacizumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.2.4 Amgen Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

11.2.5 Amgen Recent Developments

11.3 Aark Pharmaceuticals

11.3.1 Aark Pharmaceuticals Company Information

11.3.2 Aark Pharmaceuticals Overview

11.3.3 Aark Pharmaceuticals Bevacizumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.3.4 Aark Pharmaceuticals Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

11.3.5 Aark Pharmaceuticals Recent Developments

11.4 Beacon Pharmaceuticals Limited

11.4.1 Beacon Pharmaceuticals Limited Company Information

11.4.2 Beacon Pharmaceuticals Limited Overview

11.4.3 Beacon Pharmaceuticals Limited Bevacizumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.4.4 Beacon Pharmaceuticals Limited Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

11.4.5 Beacon Pharmaceuticals Limited Recent Developments

11.5 Balaji Medical Services Private Limited

11.5.1 Balaji Medical Services Private Limited Company Information

11.5.2 Balaji Medical Services Private Limited Overview

11.5.3 Balaji Medical Services Private Limited Bevacizumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.5.4 Balaji Medical Services Private Limited Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

11.5.5 Balaji Medical Services Private Limited Recent Developments

11.6 MVASI (bevacizumab)

11.6.1 MVASI (bevacizumab) Company Information

11.6.2 MVASI (bevacizumab) Overview

11.6.3 MVASI (bevacizumab) Bevacizumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.6.4 MVASI (bevacizumab) Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

11.6.5 MVASI (bevacizumab) Recent Developments

11.7 Mylan

11.7.1 Mylan Company Information

11.7.2 Mylan Overview

11.7.3 Mylan Bevacizumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.7.4 Mylan Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

11.7.5 Mylan Recent Developments

12 Industry Chain and Sales Channels Analysis

12.1 Bevacizumab Industry Chain Analysis

12.2 Bevacizumab Key Raw Materials

12.2.1 Key Raw Materials

12.2.2 Raw Materials Key Suppliers

12.3 Bevacizumab Production Mode & Process

12.4 Bevacizumab Sales and Marketing

12.4.1 Bevacizumab Sales Channels

12.4.2 Bevacizumab Distributors

12.5 Bevacizumab Customers

13 Market Dynamics

13.1 Bevacizumab Industry Trends

13.2 Bevacizumab Market Drivers

13.3 Bevacizumab Market Challenges

13.4 Bevacizumab Market Restraints

14 Key Findings in The Global Bevacizumab Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

FEATURED COMPANIES

Genentech Inc

Amgen Inc

Aark Pharmaceuticals

Beacon Pharmaceuticals Limited

Mylan NV

Balaji Medical Services Private Limited

MVASI (bevacizumab)

List of Tables

Table 1. Global Bevacizumab Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Table 2. Major Manufacturers of Avastin (bevacizumab)

Table 3. Major Manufacturers of Mvasi (bevacizumab-awwb)

Table 4. Global Bevacizumab Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Table 5. Global Bevacizumab Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 6. Global Bevacizumab Revenue by Region (2019-2024) & (US$ Million)

Table 7. Global Bevacizumab Revenue by Region (2025-2030) & (US$ Million)

Table 8. Global Bevacizumab Revenue Market Share by Region (2019-2024)

Table 9. Global Bevacizumab Revenue Market Share by Region (2025-2030)

Table 10. Global Bevacizumab Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 11. Global Bevacizumab Sales by Region (2019-2024) & (K Units)

Table 12. Global Bevacizumab Sales by Region (2025-2030) & (K Units)

Table 13. Global Bevacizumab Sales Market Share by Region (2019-2024)

Table 14. Global Bevacizumab Sales Market Share by Region (2025-2030)

Table 15. Global Bevacizumab Sales by Manufacturers (2019-2024) & (K Units)

Table 16. Global Bevacizumab Sales Share by Manufacturers (2019-2024)

Table 17. Global Bevacizumab Revenue by Manufacturers (2019-2024) & (US$ Million)

Table 18. Global Bevacizumab Revenue Share by Manufacturers (2019-2024)

Table 19. Global Key Players of Bevacizumab, Industry Ranking, 2022 VS 2023 VS 2024

Table 20. Bevacizumab Price by Manufacturers 2019-2024 (USD/Unit)

Table 21. Global Bevacizumab Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 22. Global Bevacizumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bevacizumab as of 2023)

Table 23. Global Key Manufacturers of Bevacizumab, Manufacturing Base Distribution and Headquarters

Table 24. Global Key Manufacturers of Bevacizumab, Product Offered and Application

Table 25. Global Key Manufacturers of Bevacizumab, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Bevacizumab Sales by Type (2019-2024) & (K Units)

Table 28. Global Bevacizumab Sales by Type (2025-2030) & (K Units)

Table 29. Global Bevacizumab Sales Share by Type (2019-2024)

Table 30. Global Bevacizumab Sales Share by Type (2025-2030)

Table 31. Global Bevacizumab Revenue by Type (2019-2024) & (US$ Million)

Table 32. Global Bevacizumab Revenue by Type (2025-2030) & (US$ Million)

Table 33. Global Bevacizumab Revenue Share by Type (2019-2024)

Table 34. Global Bevacizumab Revenue Share by Type (2025-2030)

Table 35. Bevacizumab Price by Type (2019-2024) & (USD/Unit)

Table 36. Global Bevacizumab Price Forecast by Type (2025-2030) & (USD/Unit)

Table 37. Global Bevacizumab Sales by Application (2019-2024) & (K Units)

Table 38. Global Bevacizumab Sales by Application (2025-2030) & (K Units)

Table 39. Global Bevacizumab Sales Share by Application (2019-2024)

Table 40. Global Bevacizumab Sales Share by Application (2025-2030)

Table 41. Global Bevacizumab Revenue by Application (2019-2024) & (US$ Million)

Table 42. Global Bevacizumab Revenue by Application (2025-2030) & (US$ Million)

Table 43. Global Bevacizumab Revenue Share by Application (2019-2024)

Table 44. Global Bevacizumab Revenue Share by Application (2025-2030)

Table 45. Bevacizumab Price by Application (2019-2024) & (USD/Unit)

Table 46. Global Bevacizumab Price Forecast by Application (2025-2030) & (USD/Unit)

Table 47. US & Canada Bevacizumab Sales by Type (2019-2024) & (K Units)

Table 48. US & Canada Bevacizumab Sales by Type (2025-2030) & (K Units)

Table 49. US & Canada Bevacizumab Revenue by Type (2019-2024) & (US$ Million)

Table 50. US & Canada Bevacizumab Revenue by Type (2025-2030) & (US$ Million)

Table 51. US & Canada Bevacizumab Sales by Application (2019-2024) & (K Units)

Table 52. US & Canada Bevacizumab Sales by Application (2025-2030) & (K Units)

Table 53. US & Canada Bevacizumab Revenue by Application (2019-2024) & (US$ Million)

Table 54. US & Canada Bevacizumab Revenue by Application (2025-2030) & (US$ Million)

Table 55. US & Canada Bevacizumab Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 56. US & Canada Bevacizumab Revenue by Country (2019-2024) & (US$ Million)

Table 57. US & Canada Bevacizumab Revenue by Country (2025-2030) & (US$ Million)

Table 58. US & Canada Bevacizumab Sales by Country (2019-2024) & (K Units)

Table 59. US & Canada Bevacizumab Sales by Country (2025-2030) & (K Units)

Table 60. Europe Bevacizumab Sales by Type (2019-2024) & (K Units)

Table 61. Europe Bevacizumab Sales by Type (2025-2030) & (K Units)

Table 62. Europe Bevacizumab Revenue by Type (2019-2024) & (US$ Million)

Table 63. Europe Bevacizumab Revenue by Type (2025-2030) & (US$ Million)

Table 64. Europe Bevacizumab Sales by Application (2019-2024) & (K Units)

Table 65. Europe Bevacizumab Sales by Application (2025-2030) & (K Units)

Table 66. Europe Bevacizumab Revenue by Application (2019-2024) & (US$ Million)

Table 67. Europe Bevacizumab Revenue by Application (2025-2030) & (US$ Million)

Table 68. Europe Bevacizumab Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 69. Europe Bevacizumab Revenue by Country (2019-2024) & (US$ Million)

Table 70. Europe Bevacizumab Revenue by Country (2025-2030) & (US$ Million)

Table 71. Europe Bevacizumab Sales by Country (2019-2024) & (K Units)

Table 72. Europe Bevacizumab Sales by Country (2025-2030) & (K Units)

Table 73. China Bevacizumab Sales by Type (2019-2024) & (K Units)

Table 74. China Bevacizumab Sales by Type (2025-2030) & (K Units)

Table 75. China Bevacizumab Revenue by Type (2019-2024) & (US$ Million)

Table 76. China Bevacizumab Revenue by Type (2025-2030) & (US$ Million)

Table 77. China Bevacizumab Sales by Application (2019-2024) & (K Units)

Table 78. China Bevacizumab Sales by Application (2025-2030) & (K Units)

Table 79. China Bevacizumab Revenue by Application (2019-2024) & (US$ Million)

Table 80. China Bevacizumab Revenue by Application (2025-2030) & (US$ Million)

Table 81. Asia Bevacizumab Sales by Type (2019-2024) & (K Units)

Table 82. Asia Bevacizumab Sales by Type (2025-2030) & (K Units)

Table 83. Asia Bevacizumab Revenue by Type (2019-2024) & (US$ Million)

Table 84. Asia Bevacizumab Revenue by Type (2025-2030) & (US$ Million)

Table 85. Asia Bevacizumab Sales by Application (2019-2024) & (K Units)

Table 86. Asia Bevacizumab Sales by Application (2025-2030) & (K Units)

Table 87. Asia Bevacizumab Revenue by Application (2019-2024) & (US$ Million)

Table 88. Asia Bevacizumab Revenue by Application (2025-2030) & (US$ Million)

Table 89. Asia Bevacizumab Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 90. Asia Bevacizumab Revenue by Region (2019-2024) & (US$ Million)

Table 91. Asia Bevacizumab Revenue by Region (2025-2030) & (US$ Million)

Table 92. Asia Bevacizumab Sales by Region (2019-2024) & (K Units)

Table 93. Asia Bevacizumab Sales by Region (2025-2030) & (K Units)

Table 94. Middle East, Africa and Latin America Bevacizumab Sales by Type (2019-2024) & (K Units)

Table 95. Middle East, Africa and Latin America Bevacizumab Sales by Type (2025-2030) & (K Units)

Table 96. Middle East, Africa and Latin America Bevacizumab Revenue by Type (2019-2024) & (US$ Million)

Table 97. Middle East, Africa and Latin America Bevacizumab Revenue by Type (2025-2030) & (US$ Million)

Table 98. Middle East, Africa and Latin America Bevacizumab Sales by Application (2019-2024) & (K Units)

Table 99. Middle East, Africa and Latin America Bevacizumab Sales by Application (2025-2030) & (K Units)

Table 100. Middle East, Africa and Latin America Bevacizumab Revenue by Application (2019-2024) & (US$ Million)

Table 101. Middle East, Africa and Latin America Bevacizumab Revenue by Application (2025-2030) & (US$ Million)

Table 102. Middle East, Africa and Latin America Bevacizumab Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 103. Middle East, Africa and Latin America Bevacizumab Revenue by Country (2019-2024) & (US$ Million)

Table 104. Middle East, Africa and Latin America Bevacizumab Revenue by Country (2025-2030) & (US$ Million)

Table 105. Middle East, Africa and Latin America Bevacizumab Sales by Country (2019-2024) & (K Units)

Table 106. Middle East, Africa and Latin America Bevacizumab Sales by Country (2025-2030) & (K Units)

Table 107. Genentech Company Information

Table 108. Genentech Description and Major Businesses

Table 109. Genentech Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 110. Genentech Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 111. Genentech Recent Developments

Table 112. Amgen Company Information

Table 113. Amgen Description and Major Businesses

Table 114. Amgen Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 115. Amgen Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 116. Amgen Recent Developments

Table 117. Aark Pharmaceuticals Company Information

Table 118. Aark Pharmaceuticals Description and Major Businesses

Table 119. Aark Pharmaceuticals Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 120. Aark Pharmaceuticals Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 121. Aark Pharmaceuticals Recent Developments

Table 122. Beacon Pharmaceuticals Limited Company Information

Table 123. Beacon Pharmaceuticals Limited Description and Major Businesses

Table 124. Beacon Pharmaceuticals Limited Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 125. Beacon Pharmaceuticals Limited Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 126. Beacon Pharmaceuticals Limited Recent Developments

Table 127. Balaji Medical Services Private Limited Company Information

Table 128. Balaji Medical Services Private Limited Description and Major Businesses

Table 129. Balaji Medical Services Private Limited Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 130. Balaji Medical Services Private Limited Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 131. Balaji Medical Services Private Limited Recent Developments

Table 132. MVASI (bevacizumab) Company Information

Table 133. MVASI (bevacizumab) Description and Major Businesses

Table 134. MVASI (bevacizumab) Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 135. MVASI (bevacizumab) Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 136. MVASI (bevacizumab) Recent Developments

Table 137. Mylan Company Information

Table 138. Mylan Description and Major Businesses

Table 139. Mylan Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 140. Mylan Bevacizumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 141. Mylan Recent Developments

Table 142. Key Raw Materials Lists

Table 143. Raw Materials Key Suppliers Lists

Table 144. Bevacizumab Distributors List

Table 145. Bevacizumab Customers List

Table 146. Bevacizumab Market Trends

Table 147. Bevacizumab Market Drivers

Table 148. Bevacizumab Market Challenges

Table 149. Bevacizumab Market Restraints

Table 150. Research Programs/Design for This Report

Table 151. Key Data Information from Secondary Sources

Table 152. Key Data Information from Primary Sources

List of Figures

Figure 1. Bevacizumab Product Picture

Figure 2. Global Bevacizumab Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Bevacizumab Market Share by Type in 2023 & 2030

Figure 4. Avastin (bevacizumab) Product Picture

Figure 5. Mvasi (bevacizumab-awwb) Product Picture

Figure 6. Global Bevacizumab Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 7. Global Bevacizumab Market Share by Application in 2023 & 2030

Figure 8. Cancer

Figure 9. Eye Diease

Figure 10. Bevacizumab Report Years Considered

Figure 11. Global Bevacizumab Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Bevacizumab Revenue 2019-2030 (US$ Million)

Figure 13. Global Bevacizumab Revenue Market Share by Region in Percentage: 2023 Versus 2030

Figure 14. Global Bevacizumab Revenue Market Share by Region (2019-2030)

Figure 15. Global Bevacizumab Sales 2019-2030 ((K Units)

Figure 16. Global Bevacizumab Sales Market Share by Region (2019-2030)

Figure 17. US & Canada Bevacizumab Sales YoY (2019-2030) & (K Units)

Figure 18. US & Canada Bevacizumab Revenue YoY (2019-2030) & (US$ Million)

Figure 19. Europe Bevacizumab Sales YoY (2019-2030) & (K Units)

Figure 20. Europe Bevacizumab Revenue YoY (2019-2030) & (US$ Million)

Figure 21. China Bevacizumab Sales YoY (2019-2030) & (K Units)

Figure 22. China Bevacizumab Revenue YoY (2019-2030) & (US$ Million)

Figure 23. Asia (excluding China) Bevacizumab Sales YoY (2019-2030) & (K Units)

Figure 24. Asia (excluding China) Bevacizumab Revenue YoY (2019-2030) & (US$ Million)

Figure 25. Middle East, Africa and Latin America Bevacizumab Sales YoY (2019-2030) & (K Units)

Figure 26. Middle East, Africa and Latin America Bevacizumab Revenue YoY (2019-2030) & (US$ Million)

Figure 27. The Bevacizumab Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023

Figure 28. The Top 5 and 10 Largest Manufacturers of Bevacizumab in the World: Market Share by Bevacizumab Revenue in 2023

Figure 29. Global Bevacizumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 30. Global Bevacizumab Sales Market Share by Type (2019-2030)

Figure 31. Global Bevacizumab Revenue Market Share by Type (2019-2030)

Figure 32. Global Bevacizumab Sales Market Share by Application (2019-2030)

Figure 33. Global Bevacizumab Revenue Market Share by Application (2019-2030)

Figure 34. US & Canada Bevacizumab Sales Market Share by Type (2019-2030)

Figure 35. US & Canada Bevacizumab Revenue Market Share by Type (2019-2030)

Figure 36. US & Canada Bevacizumab Sales Market Share by Application (2019-2030)

Figure 37. US & Canada Bevacizumab Revenue Market Share by Application (2019-2030)

Figure 38. US & Canada Bevacizumab Revenue Share by Country (2019-2030)

Figure 39. US & Canada Bevacizumab Sales Share by Country (2019-2030)

Figure 40. U.S. Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 41. Canada Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 42. Europe Bevacizumab Sales Market Share by Type (2019-2030)

Figure 43. Europe Bevacizumab Revenue Market Share by Type (2019-2030)

Figure 44. Europe Bevacizumab Sales Market Share by Application (2019-2030)

Figure 45. Europe Bevacizumab Revenue Market Share by Application (2019-2030)

Figure 46. Europe Bevacizumab Revenue Share by Country (2019-2030)

Figure 47. Europe Bevacizumab Sales Share by Country (2019-2030)

Figure 48. Germany Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 49. France Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 50. U.K. Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 51. Italy Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 52. Russia Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 53. China Bevacizumab Sales Market Share by Type (2019-2030)

Figure 54. China Bevacizumab Revenue Market Share by Type (2019-2030)

Figure 55. China Bevacizumab Sales Market Share by Application (2019-2030)

Figure 56. China Bevacizumab Revenue Market Share by Application (2019-2030)

Figure 57. Asia Bevacizumab Sales Market Share by Type (2019-2030)

Figure 58. Asia Bevacizumab Revenue Market Share by Type (2019-2030)

Figure 59. Asia Bevacizumab Sales Market Share by Application (2019-2030)

Figure 60. Asia Bevacizumab Revenue Market Share by Application (2019-2030)

Figure 61. Asia Bevacizumab Revenue Share by Region (2019-2030)

Figure 62. Asia Bevacizumab Sales Share by Region (2019-2030)

Figure 63. Japan Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 64. South Korea Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 65. China Taiwan Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 66. Southeast Asia Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 67. India Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 68. Middle East, Africa and Latin America Bevacizumab Sales Market Share by Type (2019-2030)

Figure 69. Middle East, Africa and Latin America Bevacizumab Revenue Market Share by Type (2019-2030)

Figure 70. Middle East, Africa and Latin America Bevacizumab Sales Market Share by Application (2019-2030)

Figure 71. Middle East, Africa and Latin America Bevacizumab Revenue Market Share by Application (2019-2030)

Figure 72. Middle East, Africa and Latin America Bevacizumab Revenue Share by Country (2019-2030)

Figure 73. Middle East, Africa and Latin America Bevacizumab Sales Share by Country (2019-2030)

Figure 74. Brazil Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 75. Mexico Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 76. Turkey Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 77. Israel Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 78. GCC Countries Bevacizumab Revenue (2019-2030) & (US$ Million)

Figure 79. Bevacizumab Value Chain

Figure 80. Bevacizumab Production Process

Figure 81. Channels of Distribution

Figure 82. Distributors Profiles

Figure 83. Bottom-up and Top-down Approaches for This Report

Figure 84. Data Triangulation

Figure 85. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions